Evaluating the Role of Ruxolitinib as Treatment of Graft-Versus-Host Disease
Tania Jain, MBBS, discusses the role of ruxolitinib as treatment of graft-versus-host disease.
Tania Jain, MBBS, assistant professor at Johns Hopkins University, discusses the role of ruxolitinib (Jakafi) as treatment of graft-versus-host disease (GVHD).
At her institution, she has used ruxolitinib as treatment of GVHD for patients with grade 2 through 4 disease. However, because of the biology of GVHD, responses are observed more frequently in patients with grade 2 versus grades 3 and 4 GVHD. This is consistent with data that has been observed in the REACH-1 and REACH-2 clinical trials.
Although there are responses with ruxolitinib, physicians should be wary of potential infections or cytopenias, Jain says. Physicians should keep these concerns in mind as they use the agent.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
